AB SCIENCE news, videos and press releases - Page 4
For more news please use our advanced search feature.
AB SCIENCE - More news...
AB SCIENCE - More news...
- AB Science to present at two upcoming conferences in September 2019, the NewsMakers 2019 Healthcare conference and the H.C. Wainwright Healthcare Conference
- AB Science is providing a summary of the web conference held on June 5, 2019
- AB Science is providing a summary of the web conference held on 4 June 2019
- AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference
- AB Science provides an update on the restructuring of its clinical development department in 2018
- AB Science announces that the masitinib phase 3 study in Alzheimer's disease has completed patient recruitment
- AB Science announces the publication of a previously unknown mechanism linked to the progression of ALS and that further reinforces the rationale why masitinib might be protective in ALS
- AB Science today reports its revenues for the first half of 2018
- AB Science reports positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancer
- AB Science situation and future prospects presented during the Combined General Shareholders' Meeting held on July 29 2018
- AB Science reports positive IDMC recommendation based on an interim analysis of the masitinib phase 3 study in prostate cancer
- AB Science provides update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosis
- AB Science reports today its annual financials as of 31 December 2017 and provides an update on its activities
- AB Science announces that the CHMP has adopted a negative opinion for the marketing authorization of masitinib in Amyotrophic Lateral Sclerosis
- AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive multiple sclerosis with no requirement to increase the sample size
- AB Science announces the publication of Preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments
- Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight
- AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017
- AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment
- AB Science reports its revenue for the first half of 2017
- AB Science announces issuance of a new European patent for protecting the use of masitinib in pancreatic cancer patients
- AB Science Presents Supportive Data from its Phase 3 Study in Severe Systemic Mastocytosis at the 22nd Congress of the European Hematology Association (EHA)
- AB Science presents phase 3 data for masitinib in amyotrophic lateral sclerosis (ALS) at the European Network for the Cure of ALS (ENCALS) annual meeting
- AB Science announces that CHMP has adopted a negative opinion for masitinib in indolent systemic mastocytosis, primarily due to GCP inspection findings
- AB Science provides the summary of both conference calls held on May 12, 2017, following ANSM decision requesting suspension of masitinib clinical studies conducted in France by AB Science
- AB Science announces that ANSM requested the temporary suspension of clinical studies conducted in France following deviations from Good Clinical Practice (GCP) standards
- AB Science reports today its annual financials as of 31 December 2016 and provides an update on its activities
- AB Science announces that masitinib study in primary and secondary progressive forms of multiple sclerosis has passed its non-futility test at 2 years
- AB Science announces positive top-line results of final analysis from study AB10015 of masitinib in amyotrophic lateral sclerosis (ALS)
- AB Science announces that Frontiers in Aging Neuroscience publishes a comprehensive review on the future potential of masitinib in amyotrophic lateral sclerosis (ALS)
